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Early-Life Experience Decreases Drug-Induced
Reinstatement of Morphine CPP in Adulthood via
Microglial-Specific Epigenetic Programming of
Anti-Inflammatory IL-10 Expression
Jaclyn M. Schwarz,1 Mark R. Hutchinson,2 and Staci D. Bilbo1
1Department of Psychology and Neuroscience, Duke University, Durham, North Carolina 27705, 2Discipline of Pharmacology and Discipline of Physiology,
School of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia 5005
A critical component of drug addiction research involves identifying novel biological mechanisms and environmental predictors of risk
or resilience to drug addiction and associated relapse. Increasing evidence suggests microglia and astrocytes can profoundly affect the
physiological and addictive properties of drugs of abuse, including morphine. We report that glia within the rat nucleus accumbens
(NAcc) respond to morphine with an increase in cytokine/chemokine expression, which predicts future reinstatement of morphine
conditioned place preference (CPP) following a priming dose of morphine. This glial response to morphine is influenced by early-life
experience. A neonatal handling paradigm that increases the quantity and quality of maternal care significantly increases baseline
expression of the anti-inflammatory cytokine IL-10 within the NAcc, attenuates morphine-induced glial activation, and prevents the
subsequent reinstatement of morphine CPP in adulthood. IL-10 expression within the NAcc and reinstatement of CPP are negatively
correlated, suggesting a protective role for this specific cytokine against morphine-induced glial reactivity and drug-induced reinstate-
ment of morphine CPP. Neonatal handling programs the expression of IL-10 within the NAcc early in development, and this is maintained
into adulthood via decreased methylation of the IL-10 gene specifically within microglia. The effect of neonatal handling is mimicked by
pharmacological modulation of glia in adulthood with ibudilast, which increases IL-10 expression, inhibits morphine-induced glial
activation within the NAcc, and prevents reinstatement of morphine CPP. Taken together, we have identified a novel gene  early-life
environment interaction on morphine-induced glial activation and a specific role for glial activation in drug-induced reinstatement of
drug-seeking behavior.
Introduction
The neural pathways underlying reward induced by drugs of
abuse are well known. Despite this, the mechanisms underlying
an individual’s risk or resilience to addiction and drug abuse
potential remain poorly understood. Many factors affect an indi-
vidual’s risk of addiction, including genetic, environmental, and
physiological factors. Of these factors, the early-life environment
of an individual may be especially critical. Early-life stress in ro-
dents can increase measures of self-administration and condi-
tioned place preference (CPP) to drugs of abuse (Kosten et al.,
2000; Jaworski et al., 2005; Moffett et al., 2007; Michaels and
Holtzman, 2008), although the effects of early-life stress are de-
pendent upon the paradigm used and the behavioral endpoint
measured (Lu et al., 2003). In contrast, neonatal handling para-
digms that enhance maternal care reduce measures of reward/
dependency to drugs of abuse in adulthood (Jaworski et al., 2005;
Moffett et al., 2007; Campbell and Spear, 1999; Sternberg and
Ridgway, 2003). These examples of long-term “programming” in
brain and behavior are often attributed to changes in stress re-
sponsiveness that in turn impact neural function. However, re-
search from our laboratory provides evidence that early-life
events can permanently alter immune function within the brain,
which has long-term consequences for neural function and be-
havior. In particular, we have reported that neonatal handling
significantly attenuates the long-term adverse consequences of a
neonatal infection via a long-term decrease in glial cell reactivity
within the brain (Bilbo et al., 2007).
Glia, including microglia and astrocytes, are the most abun-
dant cell type in the brain and the primary immunocompetent
cells of the CNS. Notably, glial cells are activated by drugs of
abuse, and their activation and subsequent release of cytokines
and chemokines can impact the physiological and addictive
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properties of drugs of abuse, including morphine. Morphine-
induced proinflammatory glial activation alters neuronal excit-
ability and synaptic connectivity, opposes morphine-induced
analgesia, and increases tolerance, respiratory depression, with-
drawal, and reward to morphine (Bland et al., 2010; Hutchinson
et al., 2008a, 2009; Narita et al., 2008).
Given these collective findings, the hypotheses that guided the
research presented are as follows: (1) drugs of abuse activate glia,
thus increasing the likelihood of abuse, and (2) attenuating/pre-
venting morphine-induced glial activation via early-life handling
should therefore reduce abuse liability later in life. We present the
following evidence in support of these hypotheses: (1) morphine
activates glia within the nucleus accumbens (NAcc), inducing a
rapid increase in cytokines and chemokines; (2) neonatal han-
dling increases expression of the anti-inflammatory cytokine IL-
10, attenuates morphine-induced glial activation within the
NAcc, and protects these rats from drug-induced reinstatement
of morphine CPP; and (3) treatment of adult rats with a glial
modulator, ibudilast, mimics neonatal handling by increasing
IL-10 expression, blocking glial activation within the NAcc, and
preventing reinstatement of CPP. Neonatal handling increases
IL-10 expression postnatally, and this is maintained into adult-
hood via decreased methylation of the IL-10 gene specifically
within microglia of the NAcc. Thus, these experiments have iden-
tified a gene  early-life environment interaction on glial func-
tion within the NAcc, which predicts risk versus resilience for
relapse liability in a model of addiction.
Materials and Methods
Subjects
Adult male and female Sprague Dawley rats (55– 65 d) were obtained
from Harlan and housed in polypropylene cages with ad libitum access to
food and water. The colony was maintained at 22°C on a 12:12 h light-
dark cycle (lights on at 7:00 A.M. Eastern Standard Time). Males and
females were paired into breeders. Female breeders were examined daily
for confirmation of pregnancy, and male breeders were removed from
cages before the day of birth [postnatal day (P) 0]. Litters were culled on
P2 to a maximum of 10 pups/litter, retaining two females and as many
male pups as possible.
Drugs
Morphine sulfate and naloxone HCl were obtained from the National Insti-
tute of Drug Abuse Drug Inventory Supply (Rockville, MD). Ibudilast was
obtained from Sigma-Aldrich, catalog no. IO157 and dissolved in a 35%
polyethylene glycol/65% saline solution. Morphine sulfate and naloxone
HCl were prepared and are reported as free base concentrations.
Neonatal handling
Half of the litters were assigned to be handled daily (Bilbo et al., 2007;
Levine, 1967) or to remain undisturbed as nonhandled controls in home
cages. Handling occurred daily between 2:00 and 4:00 P.M. from P2 to
P20. Dams were removed from the home cage and placed into separate,
clean polycarbonate cages. Pups were removed together from the home
cage and placed into a separate cage with bedding. After 15 min, pups
were returned to the home cage followed by the dams. Male pups were
weaned on P21 and housed in sibling pairs. A maximum of two to three
pups from a litter were assigned to a single experimental group, except in
quantitative real-time reverse-transcription PCR (qRT-PCR) experi-
ments for which each animal came from a different litter to control for
possible litter effects.
Treatment and tissue collection
At P60, handled and nonhandled control male rats were injected with
either saline or morphine (4 mg/kg) subcutaneously at a volume of 1
ml/kg. Ibudilast was administered 30 min before morphine administra-
tion at 7.5 mg/kg intraperitoneally in vehicle at 1 ml/kg. Fifteen minutes
after morphine or saline administration, rats were deeply anesthetized
with a ketamine/xylazine cocktail and transcardially perfused with ice-
cold saline for 2 min to clear brain vessels of blood and peripheral cells,
thereby limiting contamination by peripheral immune factors. A portion
of spleen was collected, brains were extracted, and the NAcc (core and
shell, bregma 2.20 to 0.70) and hippocampus were rapidly microdis-
sected and snap frozen via immersion in isopentane and stored at 80°C
until further processing.
Corticosterone assessment
Total serum corticosterone concentrations were assessed using a colori-
metric enzyme immunoassay (EIA) kit from Assay Designs as described
previously (Bilbo et al., 2007). The assay was run according to the man-
ufacturer’s instructions, except that serum (5 l) was diluted 1:50 in
0.05% steroid displacement-modified assay buffer. The detection limit of
the assay is 27 pg/ml. Blood was centrifuged at 10,000 rpm at 4°C for 10
min. Supernatant (serum) was collected and stored at 20°C until the
assay.
Serum IL-10 assessment
Total serum IL-10 concentrations were assessed using a colorimetric EIA
kit from R&D Systems according to the manufacturer’s instructions,
except that serum was diluted 1:6 in assay buffer. The limit of detection
for this assay is 10 pg/ml. Blood was centrifuged at 10,000 rpm at 4°C for
10 min. Supernatant (serum) was collected and stored at 20°C until the
assay.
Quantitative real-time PCR
RNA was isolated from spleen, NAcc, or hippocampus using the TRIzol
method and DNase treated. Complimentary DNA (cDNA) was synthe-
sized from 500 ng of isolated RNA using the RT 2 First Strand Kit (catalog
no C-03; SABiosciences/Qiagen). Gene expression was measured using
quantitative real-time PCR with primers designed to measure 85 rat
inflammatory cytokines, chemokines, and receptors (catalog no. PARN-
011; SABiosciences/Qiagen) or primers listed below using the RT 2 SYBR
Green qPCR Master Mix (Cat. No PA-010; SABiosciences/Qiagen fol-
lowing the manufacturer’s protocol.
qRT-PCR analysis
Threshold amplification cycle number (Ct) was determined for each re-
action within the linear phase of the amplification plot, and relative gene
expression was determined using the 2 Ct method. Relative gene ex-
pression across groups was compared using a two-way ANOVA with
early-life experience (handled or nonhandled control) and adult treat-
ment (morphine or saline) as factors, or using a one-way ANOVA for the
effects of glial modulation in nonhandled control rats. Genes that had a
significant interaction of early-life experience and morphine treatment
with p  0.005 were pursued in subsequent experiments and presented.
Significant interactions using a two-way ANOVA were followed up with
the Holm–Sidak post hoc test, with p  0.05, to determine potential group
differences. Significant overall effects using one-way ANOVA were fol-
lowed up with the Tukey’s post hoc test, with p  0.05.
Conditioned place preference
An unbiased conditioned place preference or CPP paradigm was used for
these experiments within a two-chamber shuttle box that is divided into
two equal-sized compartments. One side of the box was white with a grid
floor and the other side of the box was black with a rod floor (catalog no
MED-CPP2-RSAT; Med Associates). The test box was dimly lit and
slightly brighter on the white side to eliminate the natural bias of the rats
for the grid floor. Activity was measured with automated data collection
using photo beam strips and a computer interface with Med-PC IV soft-
ware. On day 1, four groups of rats (n  12/group) were placed into the
chamber, alternating the side into which the animal was introduced, and
time spent in each side of the box was measured for 20 min ( pre-test).
One rat showed a strong preference for one side of the box on day 1 [the
rat spent more than two-thirds of the total time (800 s) in a particular side
of the box] and was eliminated from the experiments and replaced with
another animal. On days 2 and 3, animals had two conditioning sessions:
one in the A.M. between 8:00 and 12:00 and one in the P.M. between 1:00
and 5:00. Rats were randomly assigned to be conditioned to morphine in
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either the white or the black box during either the A.M. or P.M., coun-
terbalancing this parameter across treatment groups using an “unbiased
assignment procedure” (Cunningham et al., 2006). During the condi-
tioning sessions, rats were injected alternately with either morphine (4
mg/kg) or saline (1 ml/kg) and placed into one side of the conditioning
chamber with the guillotine door shut for 45 min. The order of admin-
istration was randomized across treatment groups. Thirty minutes be-
fore the conditioning sessions, animals were treated with either ibudilast
(7.5 mg/kg) or the vehicle. On day 4, testing occurred between 2:00 and
4:00 P.M. Rats were placed into the chamber, and the time spent in each
side of the box was measured for 20 min ( post-test). The CPP score was
determined by subtracting the time spent in the morphine-paired box
during the post-test from the time spent in the morphine-paired box
during the pre-test.
Extinction
Rats were placed into the CPP chamber with the guillotine door open for
5 min sessions three times per week. After three 5 min sessions each week,
the rats received an extinction test the next day, which consisted of a 20
min session with the guillotine door open. Time spent in the morphine-
paired box during the pre-test was subtracted from the time spent in the
morphine-paired box during each extinction test.
Hot plate analgesia test
Animals were briefly habituated to the hot plate (Columbus Instruments
for 1 min, twice, for two days with the plate off. The baseline latency to
respond to the heat (52.5°C) with a back paw-lick response or jump
attempt was measured in handled and nonhandled control rats two
times, 30 min apart from each other. After baseline pain responses are
obtained, animals were injected with 4 mg/kg morphine (subcutane-
ously) at a volume of 1 ml/kg. The latency to respond to the pain was
measured at 20, 40, 60, 90, and 120 min after morphine administration.
No animals tested reached the maximum response latency of 60 s, which
would have been used to avoid tissue damage. The maximal percentage
effectiveness (%MPE) was determined by subtracting the average base-
line response latency (obtained from two trials in the absence of mor-
phine) from the response latency obtained in the presence of morphine
and taking that as a percentage of the maximal response latency.
Pharmacokinetic analysis of morphine
Tissue morphine concentrations were quantified using a modified liquid
chromatography/mass spectrometry (LC/MS) detection method based
on the work of Somogyi et al. (2008). The MS detector (Shimadzu LCMS-
2010A) detected the compounds of interest using single ion monitoring
mode at m/z ratios of morphine: (286.05) and d3-morphine (289.05).
Detection parameters of the system were as follows: nebulizing gas flow,
4 L/min; CDL temperature, 250°C; block temperature, 300°C; probe
voltage, 3 kV; detector, 1.6 kV; CDL, 175 V; and Q array, 30 V/RF 150.
Serum samples (100 l) aliquots were added into 10 ml tapered tubes,
followed by 100 l of water and 100 l of d3-morphine internal standard
(20 ng/ml). Seven hundred microliters of glycine extraction buffer was
added and the samples were vortexed for 5 s, followed by the addition of
5 ml of hexane:ether (70:30), and rotary mixed for 20 min. Samples were
then centrifuged at 2250  g for 10 min, shaken vigorously to form a
clean interface, and centrifuged again at 2250  g for a further 10 min.
The organic fraction (4800 l) was then transferred into a separate 10
ml tapered bottom tube preloaded with 200 l of HCl (0.1 M) and vor-
texed for 60 s, followed by centrifugation at 2250  g for 10 min. Finally,
the organic fraction was aspirated and 120 l of the remaining aqueous
acid fraction was transferred in injection vials where 100 l of the sample
was injected onto a 150  2.00 mm 5u C18 column at a 0.2 ml/min flow
rate. Calibration standards range from 1 ng/ml to 150 ng/ml, and samples
above this are diluted with blank serum with the addition of the internal
standard. High (75 ng/ml), medium (20 ng/ml), and low (3.75 ng/ml)
quality control samples were assayed with each assay and are expected to
be within 10% of the nominal concentrations. The limit of quantification
is 3.75 ng/ml.
Cannulae implantation
Chronic indwelling stainless steel bilateral guide cannulae (26 g; Plastics
One) were implanted in the dorsal portion of the NAcc according to the
following coordinates: anteroposterior, 2.16 mm; mediolateral, 1.5
mm; dorsoventral, 5.75 mm (Paxinos and Watson, 2005). Cannulae
were secured with dental cement (Bosworth Trim II) and a jeweler’s
screw implanted in the skull. Dummy cannulae (33 g, 1 mm projection,
Plastics One) were placed in the guide cannulae to maintain patency. Rats
were allowed to recover for 5 d before behavioral experiments.
Microinjection procedure
Rats were microinjected with either vehicle (4% Captisol, CyDex Phar-
maceuticals; in sterile PBS) or ibudilast in vehicle, depending on the
experiment, while under light isoflurane anesthesia 1 h before morphine
treatment using an internal infusion cannula (33 g, 1 mm projection;
Plastics One). The doses of ibudilast used for infusion (23 or 230 ng) were
based on two experiments that treated glial cells (rodent or human) with
100 M ibudilast (23 ng in 1 l) in culture (Suzumura et al., 1999; Kiebala
and Maggirwar, 2011). These studies determined that 100 M ibudilast
inhibits phosphodiesterase III 35– 40%, and thereby inhibits the syn-
thesis of cytokines and chemokines from glial cells by 50 – 80%, de-
pending upon the protein of analysis. Thus we used two doses for our
initial experiments based on these culture experiments, 23 and 230 ng, to
establish a small dose–response curve to determine that 230 ng of ibudi-
last significantly attenuates morphine-induced glial activation and has
no demonstrable side effects. All injections into the NAcc were delivered
using a microinjection syringe pump (Harvard Apparatus) in a volume
of 1 l over 5 min, after which the infusion cannulae were kept in the
guide cannulae for an additional 5 min. Before conditioning with saline,
rats were placed under light isoflurane anesthesia and injection cannulae
were placed in the guide cannulae, but no liquid was infused to avoid
infusing too much liquid into the NAcc during one day. This procedure
was repeated for both days of CPP conditioning.
Histology
Once all testing was completed, rats were anesthetized and transcardially
perfused with 0.1 M PBS, followed by 4% paraformaldehyde solution.
Brains were sectioned on a cryostat (Leica) along the coronal plane at a
thickness of 50 m and were stained with cresyl violet (1% solution).
Infusion cannulae tip placement was located using light microscopy and
was mapped onto a schematic diagram of the rat brain (Paxinos and
Watson, 2005).
Microglial isolations
Microglia were isolated from NAcc tissue as previously reported (Frank
et al., 2006). Briefly, dissociated tissue was resuspended in 70% isotonic
Percoll (GE Healthcare) layered with a 50% isotonic Percoll and a final
layer of 1 PBS. Following centrifugation, two distinct layers were visi-
ble. The lower layer between the 70% and 50% Percoll phases contained
a highly enriched and quiescent population of microglia that were re-
moved and washed with 1 PBS, and taken directly through DNA ex-
traction and methylation-dependent immunoprecipitation (MeDIP).
Methylation-dependent immunoprecipitation with quantitative
real-time PCR
NAcc microdissections or isolated microglia from NAcc were homoge-
nized in lysis buffer (50 mM Tris HCl, pH 7.5, 100 mM EDTA, 100 mM
NaCl, 1% SDS), and DNA was precipitated using phenol:chloroform:
isoamyl alcohol extraction. DNA was sheared to an average size of 400 –
800 bp by sonication (confirmed by agarose gel). Two micrograms of
DNA was immunoprecipitated (IP) with a ChIP-grade 5-methylcytosine
antibody using the EpiQuick Methylated DNA Immunoprecipitation Kit
(Epigentek), ethanol precipitated, and resuspended in 10 l of elution
buffer similar to protocols reported by others (Miller et al., 2010). Two
micrograms of DNA was diluted into 10 l of elution buffer and set aside
as input (IN) DNA. Negative controls contained normal mouse IgG.
Quantitative real-time PCR analysis of 1 l of IN DNA or IP DNA was
performed using primers designed for a 100 bp region of the CpG Island
of the IL-10 gene (confirmed using CpG Island Searcher, cpgisland-
s.usc.edu/) or GAPDH. Threshold amplification cycle numbers obtained
within the linear range were used to calculate MeDIP DNA quantities and
input DNA quantities for each sample, assayed in duplicate and analyzed
using the 2 Ct method. Amplified products were further confirmed by
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electrophoresis on 1% agarose gel stained with ethidium bromide and
visualized under UV light.
Primer specifications
mRNA primers. Real-time quantitative PCR primers were obtained from
SABiosciences/Qiagen from catalog no. PARN-011 and catalog no.
QT00177618 (IL-10).
MeDIP primers. IL-10 DNA forward primer was AAGCAAGGCAGTGG
AGCA, and IL-10 DNA reverse primer was GGTGGCTTTCTAACTGGCA.
GAPDH forward primer was CTTCGCCTCTTTCAATGTGC, and
GAPDH reverse primer was GGTCAGTAGACTCTTACAGC.
Statistical analysis
A two-way ANOVA (early-life experience  morphine treatment) or a
one-way ANOVA (glial modulation in nonhandled control rats) was
used to analyze quantitative real-time PCR data for each inflammatory
gene. A two-tailed Student’s t test with p  0.05 was used to compare CPP
data from handled and nonhandled control rats alone, as well as subse-
quent reinstatement data. A two-way ANOVA (early-life experience  glial
modulation) was also used to analyze CPP data, as well as subsequent
reinstatement data from the final experiment. Extinction data were ana-
lyzed using a two-way repeated-measures ANOVA, p  0.05. Significant
interactions using a two-way ANOVA or repeated-measures ANOVA
were followed up with the Holm–Sidak post hoc test, with p  0.05, to
determine group differences. Significant overall effects using one-way
ANOVA were followed up with the Tukey’s post hoc test, with p  0.05, to
determine group differences. IL-10 expression at P10 in brain or at P60 in
spleen, corticosterone levels, and MeDIP data collected from handled
and nonhandled control rats were analyzed using a two-tailed Student’s t
test with p  0.05. All data in graphical form represent the mean  SEM.
Results
Morphine produces rapid glial activation within the NAcc
that is significantly attenuated by neonatal handling
Very little is known about the glial response to morphine, partic-
ularly in brain regions underlying reward. To characterize this,
we assessed expression levels of CD11b and glial fibrillary acidic
protein (GFAP) mRNA, two well established markers of micro-
glia and astrocyte activation, respectively, within the NAcc of
nonhandled control rats following morphine (4 mg/kg) treat-
ment. Morphine produced a rapid increase in CD11b and GFAP
within 15 min following morphine exposure that returned to
baseline within 60 min post-morphine administration (Fig. 1A;
CD11b: F(3,19)  4.81, p  0.014; GFAP: F(3,19)  9.07, p 
0.001). For comparison, we measured the expression levels of
these genes within the hippocampus of the same animals and
determined that morphine does not produce the same glial acti-
vation observed in the NAcc (Fig. 1B; CD11b: F(3,19)  1.38, p 
0.277; GFAP: F(3,19)  2.62, p  0.080).
To further characterize the inflammatory factors produced
within the NAcc following morphine administration and how
they may be affected by neonatal handling, neonatally handled
and nonhandled control rats were treated with saline or mor-
phine and inflammatory gene expression was measured within
the NAcc after 15 or 30 min. At the 15 min time point, 11 genes
showed a significant interaction of early-life experience and mor-
phine treatment (Fig. 1C; two-way ANOVA interaction for early-
life experience  morphine treatment, p  0.005 for all genes
depicted). Ten genes were significantly upregulated and one
gene, the neuronal cytokine CX3CL1 (fractalkine), was signifi-
cantly downregulated within the NAcc following morphine treat-
ment. Neonatal handling completely blocked the morphine-
induced cytokine/chemokine response within the NAcc.
Notably, the anti-inflammatory cytokine, IL-10, was significantly
upregulated within the NAcc of handled rats at baseline when
compared to nonhandled controls (two-way ANOVA, early-life
experience  morphine treatment interaction: F(1,11)  14.700;
p  0.005; post hoc, p  0.012). At the 30 min time point, the
cytokine/chemokine response was resolved (data not shown), in-
dicating that the glial response to morphine within the NAcc is
both robust and rapid.
Neonatal handling does not affect baseline IL-10 mRNA
expression within the peripheral immune system
To assess the peripheral cytokine response to morphine in han-
dled and nonhandled control rats, serum protein levels of the
proinflammatory cytokine, IL-1, and the anti-inflammatory cy-
tokine, IL-10, were measured at baseline and at 45 min following
morphine administration in handled and nonhandled control
rats. IL-1 and IL-10 were undetectable at baseline in the serum
of handled and nonhandled control rats. Following morphine
treatment, IL-1 remained undetectable (data not shown); how-
ever, IL-10 levels were significantly elevated. Interestingly, this
increase in serum IL-10 was significantly attenuated in handled
rats compared to nonhandled control rats (Fig. 2A; t9 2.69,
p  0.024). These data indicate that in contrast to the proinflam-
matory glial response within the CNS, morphine is immunosup-
pressive within the periphery, consistent with the large literature
on this phenomenon (Budd, 2006; Sacerdote, 2008). Moreover,
this suppression is modulated by early-life experience.
To explore the etiology of the group difference in serum IL-10
following morphine treatment, we measured IL-10 mRNA
within the spleen to assess whether baseline expression of this
gene was differentially regulated by neonatal handling as it was in
the brain. While we had detected a 4-fold increase in the baseline
expression of IL-10 mRNA within the NAcc of handled rats; we
found no such group difference within the spleen (Fig. 2B; t18
1.05, p  0.307), consistent with the lack of protein difference
seen in the serum of handled and nonhandled control data. To-
gether, these data indicate that morphine is immunosuppressive
within the periphery, but that neonatal handling does not pro-
gram baseline IL-10 expression within the peripheral immune
system as it does within the brain. Rather, we hypothesize that the
difference in peripheral immunosuppression following morphine
administration between handled and nonhandled control rats is
driven by the differential glial response within the NAcc, as it has
been reported that the NAcc is necessary for the peripheral immu-
nosuppression induced by morphine (Saurer et al., 2008, 2009).
Neonatal handling attenuates morphine CPP and blocks
subsequent reinstatement of CPP following morphine
reexposure
Having determined that neonatal handling can significantly at-
tenuate morphine-induced gilal activation within the NAcc in
adulthood, we next sought to determine whether neonatal han-
dling would also attenuate the rewarding effects of morphine and
relapse liability in a model of addiction, conditioned place pref-
erence or CPP. Handled and nonhandled control rats were con-
ditioned to morphine (4 mg/kg) for 2 d using an unbiased CPP
paradigm. Handled and nonhandled control rats spent more
time in the morphine-paired chamber than in the saline-paired
chamber on the day of testing; however, neonatally handled rats
spent significantly less time in the morphine-paired chamber
than control rats (Fig. 3A; t16  2.08; p  0.05), indicating that
neonatal handling decreased the rewarding effects of morphine
in these rats.
Following morphine CPP, all rats began an extinction phase
whereby they were placed into the CPP environment in the ab-
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sence of morphine for a 5 min session 3 times per week and tested
for morphine CPP (20 min test) once a week for 4 weeks. A
repeated-measures ANOVA revealed a significant effect of test
day (F(4,64)  3.25; p  0.017), such that the rats spent less time in
the morphine-paired chamber during each test over the course of
the month, and a significant interaction of test day  early-life
experience (F(4,64)  2.90; p  0.028), as handled rats were faster
to extinguish the preference for the morphine-paired chamber.
Figure 1. Morphine induces a rapid increase in the expression of glial activation markers within the NAcc, but not in the hippocampus, and a rapid and robust increase in cytokine and chemokine expression
within the NAcc that is blocked by neonatal handling. Nonhandled control rats were treated with morphine (4 mg/kg) or saline and brains were collected 15, 60, or 120 min later. Analysis of CD11b, a marker of
microglial activation, and GFAP, a marker of astrocyte activation, was performed on microdissections of the NAcc and the hippocampus of the same animals. A, CD11b and GFAP mRNA were significantly
upregulated within the NAcc of control rats 15 min following morphine treatment ( p0.05, when compared to saline-treated controls). Sixty minutes after morphine administration, CD11b and GFAP mRNA
levels were declining such that they were no longer significantly different from either saline-treated controls or levels measured at 15 min. Different letters represent significant differences between groups. B,
Within the hippocampus, CD11b and GFAP mRNA were not significantly upregulated at any time point following morphine administration. C, Eleven genes showed a significant interaction following analysis
with a two-way ANOVA. Morphine significantly increased the expression of 10 inflammatory genes and significantly decreased the expression of one neuronal cytokine (CX3CL1/fractalkine). Neonatal handling
significantly blocked the morphine-induced changes in gene expression for all genes, except CX3CL1, which was significantly downregulated in handled rats when compared to nonhandled control rats treated
with saline. IL-10 mRNA showed a significantly different pattern than other genes, as IL-10 mRNA was significantly upregulated in handled rats in the absence of morphine. Treatment of handled rats with
morphine had no effect on IL-10 mRNA levels within the NAcc. (IL-10: *p  0.05 compared to all other groups; #p  0.05 compared to nonhandled control plud saline).
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By week 4, both treatment groups showed no preference for the
morphine-paired chamber (Fig. 3A). At that point, rats were in-
jected with saline before being placed in the CPP chambers,
which produced no significant reinstatement of the CPP to mor-
phine (Fig. 3B). The next day, both handled and nonhandled
control rats were injected with morphine (4 mg/kg) before being
placed in the CPP chambers, which produced a significant rein-
statement of the morphine CPP only in nonhandled control rats
(Fig. 3B; t16  2.16; p  0.04). Neonatally handled rats did not
reinstate CPP behavior following reexposure to morphine.
Attenuated morphine CPP in neonatally-handled rats is not
attributed to differences in stress, morphine analgesia, or the
pharmacokinetics of morphine
Stress is an important factor that can influence drug addiction. Two
well known, long-term effects of neonatal handling are decreased
baseline serum corticosterone and decreased stress responsiveness
(Levine, 1967; Meaney et al., 1991). To assess whether differences in
corticosterone could explain our behavioral findings in the CPP par-
adigm, serum corticosterone levels were measured at several time
points following morphine administration in a different set of rats
and at two points during the CPP paradigm presented above. As
previously reported (Bilbo et al., 2007; Meaney et al., 1991), baseline
serum corticosterone levels were significantly decreased in handled
when compared to nonhandled controls (Fig. 3C; t10-2.52, p 
0.031), yet no significant differences in the
serum corticosterone levels were measured
at any time point following morphine ad-
ministration alone (25 min: t4 0.46, p 
0.669; 60 min: t10  0.46, p  0.655; 120
min: t4  0.11, p  0.917). Serum cortico-
sterone levels were also not significantly
different immediately following the first
morphine conditioning session of CPP
(t15 0.67, p  0.513) or at the time of
CPP testing (Fig. 3D; t16 1.53, p 
0.145), and neither measure correlates with
CPP scores from the same animals (at con-
ditioning: R2  0.11, t15  1.41, p  0.178;
at CPP testing: R2  0.11, t16  1.44, p 
0.177), suggesting that serum cortico-
sterone did not significantly influence
the differential rewarding effects of mor-
phine observed in handled and non-
handled control rats.
In separate cohorts of handled and non-
handled control rats, morphine-induced
analgesia and morphine pharmacokinetics
were measured to determine whether these
factors were different between the groups, as
these factors could reflect broader differ-
ences in the glial response within the brain
and influence subsequent experiments measuring reward. Mor-
phine (4 mg/kg) produced significant analgesia 20 min (F(1,19) 
16.24; p  0.007), 40 min (F(1,19)  17.7; p  0.005), and 60 min
(F(1,19))  13.68; p  0.001) postmorphine administration quan-
tified by a hot plate test; importantly there was no significant
interaction of neonatal condition on morphine analgesia (Fig.
4A). Serum morphine concentrations were measured at 25, 60,
and 120 min following a subcutaneous dose of morphine (4 mg/
kg) in handled and nonhandled control rats. There was a signif-
icant main effect of time (F(2,19)  114.4; p  0.001), such that as
expected serum morphine levels decreased with time. There was
no main effect neonatal condition (F(2,19)  0.1; p  0.92) and
no significant interaction of time and neonatal condition
(F(2,19)  1.54; p  0.24), indicating that there were no signif-
icant differences in the pharmacokinetics of morphine be-
tween the two neonatal conditions.
IL-10 mRNA expression within the NAcc is altered by
neonatal handling and negatively correlates with the
likelihood of drug-induced reinstatement of morphine CPP
Together, the previous data indicate that neonatal handling
programs the neuroimmune system toward an anti-inflammatory
Figure 2. Neonatal handling attenuates the peripheral immunosuppressive response to
morphine, yet has no effect on baseline IL-10 expression within the peripheral immune system.
A, Peripheral IL-10 protein was measured in the serum using an ELISA at baseline or 45 min
following morphine administration in handled and nonhandled control rats. Baseline levels of
IL-10 were undetectable in serum (n  4/group). Forty-five minutes following morphine ad-
ministration, IL-10 levels were elevated; however, neonatal handling significantly decreased
(*p  0.05) IL-10 levels within the serum following morphine administration when compared
to nonhandled control rats (n  5/group). B, Baseline IL-10 mRNA within the spleen was
measured from handled and nonhandled control rats at P60. No significant differences were
detected (n  10/group).
Figure 3. Neonatal handling significantly attenuates CPP to morphine (4 mg/kg) and blocks the reinstatement of CPP following
reexposure to morphine, yet it does not affect serum corticosterone following morphine administration or during morphine CPP. A, Neo-
natal handling significantly decreased morphine preference when compared to nonhandled control rats. CPP score represents the time
spent in the morphine-paired chamber post-CPP minus the time spent in the morphine-paired chamber pre-CPP (n9/group). Following
morphineCPP,all ratswentthroughanextinctionphaseand,after4weeks,bothhandledandnonhandledcontrolratsshowedasignificant
decrease in the amount of time spent in the morphine-paired chamber. B, Injection with saline did not elicit reinstatement of CPP behavior;
however, injection with morphine (4 mg/kg) reinstated morphine CPP behavior only in nonhandled control rats (*p0.05; n9/group).
C, Baseline serum corticosterone levels were significantly increased in adult nonhandled control rats (n  6) when compared to adult
neonatally handed rats (n6; *p0.05); however, serum corticosterone levels were not significantly different between the two groups
at 25, 60, or 120 min after morphine (4 mg/kg) administration. D, Using the rats from Figure 3, A and B (handled: n8/group1 outlier;
nonhandled control: n  9/group), serum was collected immediately after the first morphine conditioning session of CPP or immediately
following the CPP test and no significant differences in serum corticosterone were measured at either instance, indicating that this factor
may not affect differences in morphine CPP between these groups.
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bias via increased expression of IL-10 mRNA in the NAcc,
prevents the glial activation and production of chemokines
and cytokines to morphine (Fig. 1C), attenuates CPP to mor-
phine (Fig. 3A), and blocks the subsequent reinstatement of
morphine CPP following drug reexposure (Fig. 3B). To fur-
ther explore these findings, baseline expression of IL-10
mRNA within the NAcc was assessed in handled and non-
handled control rats and correlated with previous morphine
CPP and reinstatement behaviors (in the rats from Fig. 3 A, B).
IL-10 mRNA levels within the NAcc did not significantly cor-
relate with initial CPP scores in the same rats (R 2  0.14,
t15  1.6, p  0.13; Fig. 5A). However, we found a significant
negative correlation between basal IL-10 expression within the
NAcc and the reinstatement of morphine CPP precipitated by
reexposure to 4 mg/kg morphine (R 2  0.30, t15 2.55, p 
0.02; Fig. 5B). These results suggest that elevated levels of the
anti-inflammatory cytokine, IL-10, within the NAcc specifically
decreases the likelihood of CPP reinstatement following drug
reexposure.
IL-10 expression within the NAcc is
programmed early in development via
glial-specific methylation of the IL-10
gene
To explore the etiology of the difference in
baseline IL-10 expression within the NAcc
(Fig. 6A), a subset of pup brains was col-
lected at P10 during the neonatal handling
paradigm. IL-10 expression within the
NAcc was already 3-fold greater in han-
dled pups than in nonhandled control
pups at this time point (t14  2.32, p 
0.03; Fig. 6B), indicating that the differ-
ence in IL-10 expression is programmed
early in development and maintained into
adulthood.
To determine a putative mechanism of
this long-term change in IL-10 expres-
sion, we analyzed relative methylation of a
CpG island on the IL-10 gene (Fig. 6C) by
using a methylated DNA immunoprecipi-
tation assay, MeDIP. DNA methylation is
a stable, long-term epigenetic change that
is predominantly established early in de-
velopment as cells are dividing and differ-
entiating and thus is a likely candidate for
the stable, long-term changes in IL-10
mRNA expression measured in the NAcc
of neonatally handled rats. We initially
found no significant differences in IL-10
gene methylation measured in whole
NAcc tissues collected from each group
(t17 0.02, p  0.98; Fig. 6D). However,
DNA methylation is a critical process of
cellular differentiation, and thus the rela-
tive methylation levels, particularly of a
cytokine gene such as IL-10, may be sig-
nificantly different between neurons, glia,
and/or microglia (Okano et al., 1999;
Bogdanović and Veenstra, 2009). Neu-
rons are not the primary producers of IL-
10, and as such this gene may be silenced
(highly methylated) in neurons, while
methylation levels would remain rela-
tively lower in cell types that produce IL-10, such as microglia
(the primary immunocompetent cells in the brain). As a result,
immunoprecipitation of methylated IL-10 from neurons would
be overrepresented in an assay of whole tissue, potentially mask-
ing any differences in IL-10 gene methylation in microglia. Thus,
we analyzed relative methylation levels of the IL-10 gene specifi-
cally in microglia rapidly isolated from NAcc tissue and detected
a nearly a 5-fold decrease in relative methylation of the IL-10 gene
in handled rats when compared to nonhandled control rats (t13
2.48, p  0.020; Fig. 6E), indicating that the early-life epige-
netic programming of IL-10 expression occurs specifically within
microglia.
Systemic treatment with the glial modulator, ibudilast,
increases IL-10 expression within the NAcc and blocks
morphine-induced glial activation
To determine whether pharmacological manipulation of glia in
adulthood could mimic the effects of neonatal handling, non-
handled control rats were treated systemically with ibudilast, a
Figure 4. Neonatal handling does not affect analgesia produced by morphine or the pharmacokinetics of morphine when
compared to nonhandled control rats in adulthood. A, Handled and nonhandled control rats were treated with 4 mg/kg morphine
(n  8/group) subcutaneously, and the latency to respond on a hot plate (52.5°C) was measured. Morphine significantly increases
the latency to respond on the hot plate when compared to saline-treated control rats [*p  0.05 compared to saline-treated
groups (n  4/group)] at the 20, 40, and 60 min time points. Analgesia was not affected by neonatal handling. B, Serum morphine
concentrations measured 25, 60, and 120 min following a subcutaneous dose of morphine (4 mg/kg) in handled and nonhandled
control rats indicates that there are no significant effects of neonatal condition on the pharmacokinetic properties of morphine
between the two groups.
Figure 5. IL-10 mRNA expression within the NAcc does not correlate with initial CPP to morphine, but it does significantly
correlate negatively with drug-induced reinstatement of morphine CPP in the same rats. A, B, From the rats used for CPP behavior
in Figure 4, IL-10 mRNA was measured within the NAcc using real-time PCR and did not significantly correlate with previously
measured morphine CPP (A), yet it did negatively correlate with previously measured reinstatement of CPP following reexposure
to 4 mg/kg morphine (n  17 animals total, 1 handled outlier; p  0.02) (B).
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well known glial modulator, or its vehi-
cle 30 min before morphine or saline ad-
ministration, and the NAcc was collected for
the analysis of cytokine and chemokine
expression. Systemic ibudilast treatment
significantly blocked all 10 of the inflam-
matory genes that were upregulated within
the NAcc following morphine administra-
tion (Fig. 7; one-way ANOVA, p  0.005 for
all genes depicted). Importantly, ibudilast
alone increased the expression of IL-10
mRNA nearly 40-fold within the NAcc.
These data indicate that, similar to the
neonatal handling paradigm, ibudilast
can shift glia into a predominantly anti-
inflammatory state, thus blocking mor-
phine-induced glial activation without
globally inhibiting glial function. Notably,
ibudilast did not block the effects of mor-
phine on CX3CL1/fractalkine (the neuro-
nal cytokine), indicating the selectivity of
this drug to glia.
Ibudilast blocks drug-induced
reinstatement of morphine CPP
following morphine reexposure
Thus far, we have determined that neonatal
handling and, similarly, systemic ibudilast
treatment can shift glial function into a pre-
dominantly anti-inflammatory state via in-
creased IL-10 expression within the NAcc
and inhibit the rapid glial activation caused
by morphine within the NAcc. We have also
determined that IL-10 mRNA expression
within the NAcc negatively correlates with
increased risk of drug-induced rein-
statement of CPP. Thus we sought to
determine whether we could definitively
block the reinstatement of morphine
CPP in nonhandled control rats by inhib-
iting morphine-induced glial activation at
the time of CPP by using ibudilast. Neona-
tally handled rats were also used in this par-
adigm for comparison. We predicted that
ibudilast would have no further effects on
the reinstatement of morphine CPP in handled rats.
Handled and nonhandled control rats were conditioned to
morphine as described previously. Thirty minutes before mor-
phine conditioning on each day, half of the rats in each group
received a systemic injection with the glial modulator, ibudilast,
or its vehicle. A two-way ANOVA for early-life experience  glial
modulation indicated a significant main effect of early-life expe-
rience on morphine CPP (F(1,46)  9.55; p  0.003; Fig. 8A).
There was no significant main effect of systemic ibudilast treat-
ment (F(1,46)  0.10; p  0.752) and no significant interaction
between early-life experience and systemic ibudilast treatment
(F(1,46)  0.18; p  0.670). Thus, neonatal handling significantly
attenuated the rewarding preference to morphine, as before,
whereas ibudilast had no effect on morphine CPP. In a control
experiment, two groups of nonhandled control rats were condi-
tioned to ibudilast (7.5 mg/kg, i.p.) or its vehicle using the CPP
paradigm. We determined that systemic ibudilast treatment
alone produced no significant reward or aversion (CPP score 
66.3  83 s) in this paradigm when compared to its vehicle (CPP
score  87.3  50 s; t8  0.19, p  0.85, data not shown).
To assess the effects of ibudilast on drug-induced reinstate-
ment of morphine CPP, all rats began an extinction phase imme-
diately after CPP whereby they were placed into the CPP
environment in the absence of morphine for a 5 min session, 3
times per week, and tested for morphine CPP (20 min test) once
a week for 4 weeks. Data collected from these tests were analyzed
using a repeated-measures ANOVA with test day, early-life expe-
rience, and glial modulation during CPP as factors, which
revealed a significant main effect of test day (F(4,164)  8.05; p 
0.0001), as all groups spent less time in the morphine-paired
chamber upon repeated testing over the course of the month. The
repeated-measures ANOVA also revealed a significant interac-
tion of early-life experience and previous glial modulation on the
rate of extinction (F(4,164)  3.29; p  0.013, data not shown),
indicating that there was a significant difference in the rate of
extinction that was differentially affected by neonatal handling
Figure 6. IL-10 expression specifically within the NAcc can be programmed early in development via decreased methylation of
the IL-10 gene. A, Represented separately in graphical form from Figure 2, IL-10 mRNA was significantly upregulated nearly 4-fold
in handled rats when compared to nonhandled control rats in the absence of morphine treatment. B, Neonatal handling (n  7)
significantly increases the expression of IL-10 within the NAcc when compared to nonhandled controls (n  8) by postnatal day 10
(*p  0.05). C, Position of the CpG Island within the IL-10 gene spanning exon 3 and intron 3 (individual CpGs represented by each
line). Primers for detection of IL-10 in immunoprecipitated and input samples were designed within this region. D, E, Neonatal
handling had no effect on relative methylation levels measured within whole tissue dissections of the NAcc using MeDIP assay
(handled: n  10; control: n  9) (D), yet a significant decrease in relative methylation levels was measured in microglial cells
isolated from the NAcc of handled rats (*p  0.05), while having no effect on total IL-10 gene levels in input samples (E).
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and gilal modulation that had occurred at the time of CPP. Spe-
cifically, neonatally handled rats and nonhandled control rats
treated with ibudilast at the time of CPP showed a faster rate of
extinction than nonhandled control rats treated with vehicle
alone. After 4 weeks, all treatment groups spent significantly less
time in the morphine-paired chamber than at the time of CPP,
indicating that the CPP had been extinguished.
Using the same rats, we next tested the reinstatement of CPP
following reexposure to morphine 8 weeks after morphine
CPP. As expected, saline treatment did not reinstate morphine-
seeking behavior (Fig. 8B). The next day, rats were treated with a
priming dose of morphine (2 mg/kg) before being placed into the
CPP environment, and data were analyzed using a two-way
ANOVA for early-life experience  previous glial modulation.
Analysis indicated a significant interaction of early-life experi-
ence  previous glial modulation (Fig. 8B; F(4,46)  4.87; p 
0.03). Specifically, only nonhandled control rats reinstated the
behavior after a priming dose of morphine when compared to
neonatally handled rats (p  0.012). Systemic treatment with
ibudilast at the time of conditioning, months earlier, completely
blocked the reinstatement of morphine-seeking behavior in non-
handled control rats when compared to vehicle-treated non-
handled control rats (p  0.004). We found the same effects on
the reinstatement of drug-seeking behavior following 4 mg/kg
morphine (significant interaction of early-life experience and
previous glial modulation: F(4,46)  3.99; p  0.045; Fig. 8C), this
time 9 weeks after initial CPP, suggesting the effect of morphine-
induced glial activation on drug-induced reinstatement of mor-
phine CPP is very long-lasting.
In a separate control experiment, ibudilast given systemically
(7.5 mg/kg, i.p.) in isolation 8 weeks before morphine CPP did
not significantly affect morphine CPP 8 weeks later (CPP score 
266.7  57 s) when compared to rats given systemic ibudilast
treatment at the time of morphine CPP (CPP score  199.9  48;
t12 0.15, p  0.59), suggesting that systemic treatment with
ibudilast does not affect the long-term rewarding or associative
properties of morphine.
Glial activation specifically within the NAcc is necessary for
drug-induced reinstatement of morphine CPP in control rats
Our evidence thus far suggests that the activation of microglia
specifically within the NAcc may be a critical component for
modulating the relative risk of drug-induced reinstatement to
morphine CPP. To determine whether glial activation specifically
Figure 7. The glial modulator, ibudilast, significantly attenuates morphine-induced proinflammatory gene expression. Pretreatment with the glial inhibitor, ibudilast, 30 min before morphine
administration significantly attenuates the morphine-induced expression of all 10 cytokines and chemokines within the NAcc. Ibudilast did not block the morphine-induced decrease in CX3CL1
mRNA (neuronal fractalkine), indicating it’s specificity to glia. Ibudilast independently increases the expression of IL-10 nearly 40-fold when compared to levels measured from vehicle (Veh)-treated,
nonhandled control rats (* and ** indicate p  0.05 from all other groups).
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within the NAcc is necessary for the ex-
pression of drug-induced reinstatement,
nonhandled control rats were implanted
with a bilateral cannula aimed at the NAcc
for infusion with ibudilast. To determine
an effective dose of ibudilast within the
brain, we assessed expression levels of
CD11b and GFAP mRNA, two well estab-
lished markers of microglia and astrocyte
activation, respectively, within the NAcc
of nonhandled control rats infused with
either vehicle or ibudilast (23 or 230 ng)
1 h before saline or morphine treatment.
We determined that 230 ng of ibudilast
infused into the NAcc could sufficiently
block the activation of both microglia
(CD11b: F(3,15)  3.16; p  0.05) and as-
trocytes (GFAP: F(3,15)  3.3; p  0.049)
caused by morphine, while 23 ng of ibudi-
last did not (Fig. 9A). We did find a signif-
icant overall increase in both CD11b and
GFAP expression within the NAcc due to
cannulation when these samples were
compared to samples from uncannulated
brains treated with or without morphine.
However, this effect of cannulation did
not preclude the increase in glial activa-
tion following morphine treatment and,
interestingly, was not reduced by ibudilast
treatment at either dose, suggesting that
this was nonspecific, on-going activation of glia within the NAcc
(data not shown).
In a separate cohort, rats were infused with either vehicle or
230 ng of ibudilast 1 h before morphine conditioning (Fig. 9B).
As seen previously with the systemic treatment, infusion of ibu-
dilast into the NAcc did not significantly affect the initial CPP to
morphine in control rats (t21 0.12; p  0.90; Fig. 9C), as both
treatment groups found morphine similarly rewarding. Follow-
ing extinction, both groups of rats showed no reinstatement of
CPP following a noncontingent dose of saline. After a priming
dose of morphine, control rats infused with the vehicle at the time
of morphine CPP showed strong reinstatement to morphine
CPP, while rats infused with ibudilast at the time of CPP did not
reinstate CPP following a priming dose of morphine (t17  2.4;
p  0.028; Fig. 9C). These data suggest that morphine-induced
activation of microglia specifically within the NAcc is necessary
for the drug-induced reinstatement of morphine CPP in control
rats.
Discussion
We report that morphine activates glia within the NAcc, rapidly
upregulating the expression of cytokines and chemokine,; and
this glial response is necessary for drug-induced reinstatement of
morphine CPP months after the initial conditioning. We dem-
onstrate that early-life experience produces an enduring anti-
inflammatory shift in this glial response via an epigenetic
modification of a cytokine gene specifically within microglia.
This change in IL-10 expression may attenuate the morphine-
induced glial response and thus block drug-induced reinstate-
ment of morphine CPP in adulthood. In support of these
findings, we also determined that pretreatment of adult control
rats with a well known glial modulator, ibudilast, increases IL-10
mRNA expression within the NAcc, blocks morphine-induced
glial activation, and prevents the drug-induced reinstatement of
morphine CPP. Thus, our data support a novel hypothesis that
morphine-induced glial activation within the NAcc at the time
of morphine CPP can profoundly affect drug-induced reinstate-
ment of CPP to morphine, and these outcomes are markedly
affected by early-life programming of glial function.
Neonatal handling programs IL-10 expression via decreased
methylation of the IL-10 gene specifically within microglia
Neonatal handling is a well known manipulation for increasing
maternal care during postnatal development, and this early-life
experience has long-term beneficial consequences for the physi-
ology and behavior of an animal. We demonstrate that neonatal
handling programs the immune system within the brain toward
an anti-inflammatory bias and increases the expression of the
anti-inflammatory cytokine, IL-10, nearly 4-fold compared to
controls. IL-10 represses the expression of proinflammatory cy-
tokines during the recovery phase of an immune response and is
important for maintaining homeostasis within the periphery and
CNS. The baseline difference in IL-10 expression between han-
dled and nonhandled control rats was established early in devel-
opment, by P10, during the course of neonatal handling.
Methylation levels of the IL-10 gene specifically within microglia
were nearly 5-fold lower in handled rats than in nonhandled
control rats, which may account for the significant life-long in-
crease in baseline IL-10 expression within the brain. DNA meth-
ylation is a stable, long-term epigenetic modification that can be
established or modified during the process of cell division and
differentiation (e.g., during early brain development). Thus, it is
not surprising that developmental changes to the epigenome re-
sulting from increased maternal care that affect adult behaviors
are a well documented phenomenon (Seckl and Meaney, 2004;
Weaver et al., 2004; Champagne et al., 2003, 2006, 2008). How-
Figure 8. Ibudilast does not affect initial morphine CPP but mimics neonatal handling by significantly blocking drug-induced
reinstatement of morphine CPP following either a priming dose (2 mg/kg) or a larger dose of morphine (4 mg/kg) in nonhandled
control rats. Neonatally handled or nonhandled control rats were given ibudilast (7.5 mg/kg) or its vehicle 30 min before each
morphine (4 mg/kg) conditioning session of CPP (n  12/group). A, Neonatal handling significantly decreased morphine prefer-
ence when compared to nonhandled control rats, and morphine CPP was unaffected by ibudilast treatment at the time of CPP
(*p  0.05; n  12/group). B, Two months later, injection with saline (1 ml/kg) alone does not reinstate morphine-seeking
behavior; however, treatment of rats with a priming dose of morphine (2 mg/kg) was sufficient to reinstate morphine-seeking
behavior in nonhandled controls previously treated with vehicle (*p  0.05 compared to all other groups). Neonatal handling sig-
nificantly blocked reinstatement of morphine CPP, and this effect was mimicked in nonhandled control rats by blocking glial
activation at the time of morphine CPP with ibudilast. C, Injection of the same rats with 4 mg/kg morphine was sufficient to
reinstate morphine-seeking behavior in nonhandled control rats initially treated with vehicle, while blocking morphine-induced
glial activation at the time of CPP and neonatal handling were each sufficient to block the drug-induced reinstatement of
morphine-seeking behavior (*p  0.05 compared to all other groups).
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ever, our data provide the first evidence to our knowledge of a
CNS cell-type-specific epigenetic change in gene expression that
significantly affects glial function and correlates with behavior.
Attenuating morphine-induced glial activation with ibudilast
attenuates drug-induced reinstatement of morphine CPP
independent of initial reward
Previous research has shown that attenuating proinflammatory
glial responses using the pharmacological modulators minocy-
cline or propentofylline can completely block morphine CPP
(Narita et al., 2006; Hutchinson et al., 2008b). Thus, we initially
predicted that decreased glial activation produced by neonatal
handling or ibudilast would attenuate morphine CPP to similar
levels and were surprised to find that ibudilast did not mimic the
effect of neonatal handling on morphine CPP. There are at least
two potential explanations for these findings. First, increased ma-
ternal care increases baseline dopaminergic tone within the
NAcc, attenuating dopamine release to sucrose, drugs, or stress
and may thereby potentially lower the hedonic impact of such
stimuli (Brake et al., 2004; Pruessner et al., 2004; Moffett et al.,
2007). Second, cytokines from peripheral leukocytes that infil-
trate the brain could also regulate aspects of morphine reward in
handled rats. We determined that IL-10 protein was significantly
increased in serum following morphine treatment in both
groups, although significantly less so in handled rats, consistent
with the literature indicating that morphine is immunosuppres-
sive within the periphery (Budd, 2006; Sacerdote, 2008). We sus-
pect that the differential glial response within the NAcc may be
driving the differential peripheral immunosuppressive response
between these groups and, consistent with this idea, others have
reported that the NAcc is necessary for the peripheral immuno-
suppression induced by morphine (Saurer et al., 2008, 2009).
Nonetheless, the contribution of peripheral immune cells to
morphine reward and relapse and their modulation by early-life
experience cannot be completely ruled out. In either case, glial
activation is likely not the exclusive underlying mechanism by
which attenuated reward is established in handled rats.
Glial activation within the NAcc is required for the
reinstatement of morphine CPP following reexposure to a
priming dose of morphine given months later
We have instead identified a critical and important role for
morphine-induced glial activation in drug-induced reinstate-
ment of drug-seeking behavior. We show that glial activation
occurs during the association between morphine and the CPP
environment. While our data suggest this glial response does not
Figure 9. Infusion of ibudilast directly into the NAcc blocks the drug-induced reinstatement of morphine CPP in control rats. A, Nonhandled control rats were implanted with bilateral cannulae
into the NAcc and infused with either vehicle or ibudilast (23 or 230 ng) 1 h before morphine (4 mg/kg) administration. Gene expression of CD11b and GFAP indicate that morphine increases the
expression of CD11b and GFAP, and infusion with ibudilast at a dose of 230 ng was sufficient to block the increase in glial activation caused by systemic morphine treatment (*p  0.05 compared
to other treatment groups). B, Atlas depiction of cannulae placement for behavioral experiments. Left hemisphere depicts the placement of the cannulae in nonhandled control rats infused with 230
ng of ibudilast (gray dots), and the right hemisphere depicts the placement of the cannulae in nonhandled control rats infused with vehicle (black dots). All atlas references are from bregma according
to Paxinos and Watson (2005). C, Infusion of ibudilast (230 ng) directly into the NAcc had no effect on morphine CPP. Following extinction, all rats showed no preference for the morphine-paired
chamber. One week later, in the same rats injection with saline (1 ml/kg) alone does not reinstate morphine-seeking behavior in any of the rats; however, treatment of rats with a priming dose of
morphine (2 mg/kg) was sufficient to reinstate morphine-seeking behavior in nonhandled controls rats, and this effect was blocked by previous infusion of 230 ng of ibudilast into the NAcc (*p 
0.05 control rats infused with ibudilast).
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alter the immediate rewarding effects of the drug, it is necessary
for drug-induced reinstatement of drug-seeking behavior
months later. These findings support a growing literature sug-
gesting that the neural mechanisms underlying the acute initial
rewarding effects of drugs are different from those underlying
drug seeking after abstinence/withdrawal from the drug (Shalev
et al., 2002; Shaham et al., 2003; Kalivas and Volkow, 2005).
Moreover, there is increasing support for a role of glia in addic-
tion (Haydon et al., 2009; Miguel-Hidalgo, 2009; Ghitza et al.,
2010). We hypothesize that the chemokines and cytokines that
are rapidly upregulated within the NAcc following morphine ex-
posure act as neuromodulators to alter neuronal activation, syn-
aptic transmission, and synaptic connectivity, a distinct function
from the traditionally defined role for cytokines and chemokines
within the brain following infection or injury. Cytokines and
chemokines, as well as their receptors, have been identified on
many cell types including microglia and astrocytes (Nitta, 1998;
Dorf et al., 2000; Croitoru-Lamoury et al., 2003); and in 2005 it
was postulated that chemokines act as neuromodulators (Adler
and Rogers, 2005).
We determined that CX3CL1, a cytokine produced in neurons
that attenuates glial function, is downregulated following mor-
phine administration, and this effect was not blocked by ibudilast
pretreatment. This suggests that as neurons within the NAcc re-
spond (likely to dopamine release), they downregulate CX3CL1
expression and release, thereby activating glia and stimulating the
production of other cytokines and chemokines that may in turn
affect synaptic function. We also demonstrate that CXCL9, a
chemokine produced in response to interferon-, is upregulated
nearly 15-fold following morphine administration, and this
chemokine has a demonstrated role as a neurotrophic factor
(Gonzalez-Perez et al., 2010; Müller et al., 2010). A more recent
literature is emerging that indicates that classical immune factors
can also modulate the release of neurotransmitters, in particular
DA within the striatum (Bezzi et al., 2001; Nicolai et al., 2010;
Rostène et al., 2011; Santello et al., 2011). Ibudilast can attenuate
DA release from NAcc neurons during an extended dosing para-
digm of physical morphine dependence/withdrawal (Bland et al.,
2009). We found that ibudilast does not attenuate morphine
CPP, suggesting that ibudilast does not attenuate the increase in
DA produced by two daily doses of morphine and therefore can-
not explain the lack of reinstatement weeks later; however these
data do not discount the potential role of immune molecules in
synaptic plasticity underlying motivation, reward, and reinstate-
ment. Thus, our understanding of these immune molecules in a
“noninjury” model requires further exploration. Our data sug-
gest that the rapid glial response to morphine specifically within
the NAcc may induce long-term changes in the greater circuit
underlying drug-induced reinstatement of CPP, and our future
research will seek to identify the specific mechanisms of these
cytokines/chemokines in this model.
Handled rats did not reinstate drug-seeking behavior after
reexposure to morphine in these experiments. While this may be
due to the fact that handled rats found morphine less rewarding
initially, the significant negative correlation between IL-10
mRNA expression within the NAcc and reinstatement of CPP
behavior suggests otherwise. We propose instead that because
handled rats have a profoundly attenuated inflammatory re-
sponse to morphine within the NAcc as a result of differential
IL-10 transcription, they are protected from the long-term
changes in neurocircuitry that occur as a result of glial activation
and affect subsequent drug-induced reinstatement of CPP de-
spite initial attenuated reward.
In closing, relapse to drug abuse following long periods of
abstinence remains one of the most difficult challenges in the
treatment of drug addiction in humans (O’Brien, 1997). Only a
small percentage of the human population succumbs to addic-
tion after exposure to drugs of abuse, yet the toll on society is
great. The handling manipulation used here likely represents the
“typical” human response to drugs of abuse, whereas nonhandled
“controls” represent the minority at increased risk for addiction.
We have identified a novel role for the neuroimmune system in
reinstatement of morphine CPP following drug reexposure. Our
data suggest that potential drug-induced reinstatement of CPP
can be programmed by early-life experience via epigenetic
changes to microglia or manipulated by adult interventions that
also target glia. Ibudilast is currently used for the treatment of
asthma and other inflammatory conditions of the CNS and is well
tolerated when given systemically in humans (Rolan et al., 2009);
thus, further research identifying the potential use of ibudilast as
a drug addiction treatment is warranted. Moreover, future re-
search that focuses on the interaction of early-life environment
and genes associated with the immune response may be a critical
next step in identifying at-risk individuals and potential treat-
ment therapies targeting glia.
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Bogdanović O, Veenstra GJ (2009) DNA methylation and methyl-CpG
binding proteins: Developmental requirements and function. Chromo-
soma 118:549 –565.
Brake WG, Zhang TY, Diorio J, Meaney MJ, Gratton A (2004) Influence of
early postnatal rearing conditions on mesocorticolimbic dopamine and
behavioural responses to psychostimulants and stressors in adult rats. Eur
J Neurosci 19:1863–1874.
Budd K (2006) Pain management: Is opioid immunosuppression a clinical
problem? Biomed Pharmacother 60:310 –317.
Campbell J, Spear LP (1999) Effects of early handling on amphetamine-
induced locomotor activation and conditioned place preference in the
adult rat. Psychopharmacology 143:183–189.
Champagne DL, Bagot RC, van Hasselt F, Ramakers G, Meaney MJ, de Kloet
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